1255 related articles for article (PubMed ID: 33155660)
1. Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
Xiao Z; Liang J; Deng Q; Song C; Yang X; Liu Z; Shao Z; Zhang K; Wang X; Li Z
Int J Mol Med; 2021 Jan; 47(1):113-124. PubMed ID: 33155660
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
3. Suppressing STAT5 signaling affects osteosarcoma growth and stemness.
Subramaniam D; Angulo P; Ponnurangam S; Dandawate P; Ramamoorthy P; Srinivasan P; Iwakuma T; Weir SJ; Chastain K; Anant S
Cell Death Dis; 2020 Feb; 11(2):149. PubMed ID: 32094348
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
5. Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.
Tang C; Zhu J; Yuan F; Yang J; Cai X; Ma C
Mol Neurobiol; 2021 Dec; 58(12):6170-6185. PubMed ID: 34463926
[TBL] [Abstract][Full Text] [Related]
6. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
[TBL] [Abstract][Full Text] [Related]
7. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
8. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling.
Sinha S; Sharma S; Vora J; Shah H; Srivastava A; Shrivastava N
J Ethnopharmacol; 2018 May; 217():23-35. PubMed ID: 29427634
[TBL] [Abstract][Full Text] [Related]
9. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
[TBL] [Abstract][Full Text] [Related]
10. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
Li Q; Su Z; Liu J; Cai L; Lu J; Lin S; Xiong Z; Li W; Zheng W; Wu J; Zhuge Q; Wu Z
Mol Cell Endocrinol; 2014 Jan; 382(1):377-384. PubMed ID: 24184771
[TBL] [Abstract][Full Text] [Related]
11. Novel indoloquinoline derivative, IQDMA, inhibits STAT5 signaling associated with apoptosis in K562 cells.
Yang SH; Chien CM; Su JC; Chen YL; Chang LS; Lin SR
J Biochem Mol Toxicol; 2008; 22(6):396-404. PubMed ID: 19111001
[TBL] [Abstract][Full Text] [Related]
12. IGF-1 stimulated upregulation of cyclin D1 is mediated via STAT5 signaling pathway in neuronal cells.
Kalita A; Gupta S; Singh P; Surolia A; Banerjee K
IUBMB Life; 2013 May; 65(5):462-71. PubMed ID: 23504816
[TBL] [Abstract][Full Text] [Related]
13. miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma.
Hu B; Mao Z; Du Q; Jiang X; Wang Z; Xiao Z; Zhu D; Wang X; Zhu Y; Wang H
Brain Res Bull; 2019 Jul; 149():21-31. PubMed ID: 30946881
[TBL] [Abstract][Full Text] [Related]
14. Terguride as a new anti-hyperprolactinemic agent: characterization in rats and dogs in comparison with bromocriptine.
Mizokawa T; Akai T; Nakada Y; Yamaguchi M; Nakagawa H; Hasan S; Rettig KJ; Wachtel H
Jpn J Pharmacol; 1993 Nov; 63(3):269-78. PubMed ID: 7906316
[TBL] [Abstract][Full Text] [Related]
15. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
Bevan JS; Burke CW
Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells.
Huang J; Zhang F; Jiang L; Hu G; Sun W; Zhang C; Ding X
Cancer Res Treat; 2017 Apr; 49(2):358-373. PubMed ID: 27488872
[TBL] [Abstract][Full Text] [Related]
17. The effect of octreotide and bromocriptine on expression of a pro-apoptotic Bax protein in rat prolactinoma.
Gruszka A; Kunert-Radek J; Pawlikowski M
Folia Histochem Cytobiol; 2004; 42(1):35-9. PubMed ID: 15046398
[TBL] [Abstract][Full Text] [Related]
18. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
[TBL] [Abstract][Full Text] [Related]
19. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo.
Dagvadorj A; Kirken RA; Leiby B; Karras J; Nevalainen MT
Clin Cancer Res; 2008 Mar; 14(5):1317-24. PubMed ID: 18316550
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptors.
Wang C; Hu ZQ; Chu M; Wang Z; Zhang WG; Wang LZ; Li CG; Wang JS
Clin Neurol Neurosurg; 2012 Apr; 114(3):241-8. PubMed ID: 22104698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
